Hypofractionation and prostate cancer: A good option for Africa?

Cancer is an emerging public health problem in Africa. According to the World Health Organization (WHO), the numbers will be doubled by 2030 because of the ageing and the growth of the population. Prostate cancer is the most common cancer among men in most African countries. Radiotherapy machines are extremely limited in Africa and therefore prostate cancer in Africa is mostly managed by urologists. However, for a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice in Africa because of limitations of surgical expertise in many countries. The disparity between the α/β ratio for late complications and the low α/β ratio for prostate cancer widens the therapeutic window when treating prostate cancer with hypofractionation. Because of the reduced number of treatment days, hypofractionation offers economic and logistic advantages, reducing the burden of the very limited radiotherapy resources in most African countries. It also increases patient convenience. A misleading assumption is that high-level radiotherapy is not feasible in low-income countries.

Introduction

Cancer is an emerging public health problem in Africa. According to the World Health Organization (WHO), the numbers will be doubled by 2030 because of the ageing and the growth of the population. Cancer prevention strategies are limited in Africa; therefore, most cancers are diagnosed at an advanced stage. A shortage of medical specialists, nurses and pathology workers contributes to a late presentation and low attendance in hospitals. Several new cancer registries have been established in African countries. Radiotherapy machines are extremely limited in Africa and therefore prostate cancer in Africa is mostly managed by urologists. However, for a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice in Africa because of limitations of surgical expertise in many countries.

An important biological parameter describing the response of tissues to fractionation is the repair capacity (α/β ratio). Late responding tissues are characterised by a relatively low α/β ratio (3–4 Gy), resulting in an enhanced sensitivity for large fraction doses. Acute responding healthy tissues and most tumours are characterised by a high α/β ratio (10 Gy) and therefore are relatively insensitive to large fraction doses, compared to tissues with low α/β ratio. Prostate cancer has a highly atypical growth pattern in comparison with other malignancies and has a low α/β ratio, probably even lower than late responding healthy tissues.

The disparity between the α/β ratio for late complications and the low α/β ratio for prostate cancer widens the therapeutic window by treating prostate cancer with hypofractionation. Hypofractionated schedules for prostate cancer have been used for many years, but only recently several randomised clinical trials have been published to study the possibility of a high therapeutic gain delivering a higher biological dose to the prostate without increasing toxicity. The question raised here is: could this shortened schedule find a place in radiation delivery in resource-constrained settings? This perspective will review the evidence and potential utilisation of hypofractionated EBRT in Africa.
Hypofractionation trials

A variety of schedules have been tested in clinical trials (see Table 1). The Dutch HYPRO trial randomised 820 intermediate- to high-risk patients to 39 fractions of 2 Gy (5 fractions/week) or 19 fractions of 3.4 Gy (3 fractions/week). This study was designed to test whether an equivalent increased dose of 12.4 Gy in 2-Gy fractions using hypofractionated EBRT would achieve a significant increase in relapse-free survival (RFS) of 10% as compared to conventional treatment. At a median follow-up of 60 months, no significant differences in RFS were achieved with rates of 80% and 77% after hypofractionation and conventional fractionation, respectively.

The CHHiP trial randomised 3216 patients with intermediate- or high-risk prostate cancer to conventional fractionation of 74 Gy in 37 fractions or two hypofractionation schedules: 57 Gy in 19 fractions or 60 Gy in 20 fractions. Hypofractionated treatment using 60 Gy in 20 fractions was found non-inferior to conventional treatment with 5-year RFS rates of 88% and 91% after conventional and hypofractionated treatment, respectively. The 57 Gy schedule was found to be inferior. The RTOG 0415 trial also demonstrated non-inferiority of hypofractionated EBRT of 70 Gy in 28 fractions versus 73.8 Gy in 41 fractions in 1115 patients with low-risk prostate cancer.

There was significantly more acute grade ≥ 2 bowel toxicity during treatment in the CHHiP and the HYPRO trials; however, the observed differences between arms had dissipated after completion of treatment. In contrast to bowel toxicity, all trials reported comparable acute bladder toxicities between treatment schemes. In terms of late toxicity, both the RTOG 0415 and the HYPRO trials demonstrated increased grade ≥ 2 bowel and bladder toxicity with hypofractionated EBRT as compared to conventional treatment. In contrast, the CHHiP trial did not find any difference in late toxicity between the arms and the authors concluded that their hypofractionated regimen of 60 Gy in 3-Gy fractions should be considered as new standard of care for EBRT of localised prostate cancer. The increase in late toxicity in the HYPRO trial was limited; for example, grade 3 nocturia (≥ 6 times/night) was reported in 19% after hypofractionation versus 13% in the conventional arm. It is questionable whether these differences are clinically relevant. Patients might prefer a slightly increased toxicity risk if the number of hospital visits can be reduced. Very recently, Catton et al. reported on 1206 patients with intermediate-risk prostate cancer and without anti-androgen therapy (ADT), randomised to 39 × 2 Gy and 20 × 3 Gy. The hypofractionated regimen was not inferior to conventional radiotherapy and was not associated with increased late toxicity. The authors concluded that the hypofractionated schedule is more convenient for patients and therefore should be considered for intermediate-risk prostate cancer. Patient selection is paramount when considering hypofractionation. Those men with compromised urinary function at baseline were at risk of late bladder toxicity, and therefore they might not be the right patients to prescribe hypofractionation.

Regarding erectile functioning, the HYPRO trial showed no significant differences between treatment arms in patients who received no or short-term ADT.

Stereotactic body radiotherapy (SBRT) delivered using gantry-based Linacs is an example of profound hypofractionation, using dose fractions of 5–10 Gy. Several small studies, mainly phase II non-randomised studies, including only low-stage prostate cancer, have been recently published. Current clinical data provide excellent short-term control rates for SBRT; toxicity induced by SBRT at the more established fraction dose of 5–8 Gy does not appear to be substantially higher as compared to conventional treatments. Future randomised trials will help determine the efficacy and safety of SBRT.

Why consider hypofractionation in Africa?

Hypofractionation offers economic and logistic advantages, reducing the burden of the very limited radiotherapy resources in most African countries. It also increases patient convenience. A misleading assumption is that the required high-level radiotherapy is not feasible in low-income countries because of costs, lack of electricity, poor transport, geopolitical instability, lack of specialised staff, and education and training activities; however, this does not hold true in all countries. Education of technical personnel and staff is feasible. Ongoing quality assurance can be supported through web-based systems, with teleconferencing in a sister institution either in Europe or in the USA. Several studies have been performed on automated treatment plan generation for prostate cancer. Generally, the automatically generated plans are considered similar or of higher quality compared to plans generated with conventional trial-and-error planning. Automated treatment planning, performed in collaboration with a partner institute to guarantee high plan quality, might be investigated. The most vital component is safe delivery which necessitates accurate quality assurance measures and on-board imaging.

Technical requirements for hypofractionation

The gold standard option includes image-guided radiotherapy with 3–4 implanted gold fiducials. Acceptable methods for image guidance include ultrasound and cone-beam computed tomography (CT). CT-based treatment planning with magnetic resonance imaging fusion allows for accurate

---

**TABLE 1: Hypofractionated protocols.**

<table>
<thead>
<tr>
<th>Risk group</th>
<th>Stage</th>
<th>Schedule</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate-high</td>
<td>cT1b-T4, any Gleason sum, PSA ≤ 60 µg/L</td>
<td>19 × 3.4 Gy</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 weekly</td>
<td></td>
</tr>
<tr>
<td>Intermediate-high</td>
<td>cT1b-T3a, any Gleason sum, PSA ≤ 30 µg/L</td>
<td>20 × 3 Gy</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 weekly</td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>cT1-2b, Gleason sum ≤ 6, PSA ≤ 20 µg/L</td>
<td>5 × 7 Gy</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 weekly</td>
<td></td>
</tr>
</tbody>
</table>

Source: Authors’ own work
volume delineation. Volumetric modulated arc therapy (VMAT) or inversely planned intensity modulated radiotherapy (IMRT) is the ideal for treatment delivery. Position verification prior to every fraction with electronic kilovoltage or megavoltage portal imaging or X-ray volumetric imaging ensures accurate delivery.

A reasonable option whether or not VMAT or IMRT techniques are available is modified forward planning with the field-in-field technique, or three-dimensional conformal therapy with higher energies.

In resource-constrained settings, setup verification with daily online electronic portal imaging and bony setup correction remains feasible with the addition of appropriate planning target volumes. This is not suitable for the weekly high-dose-per-fraction regimens but is well suited to the 19–20 fraction schedules and has been adopted in some centres in Africa.

**Conclusions**

Several randomised clinical trials have shown the efficacy and safety of hypofractionated EBRT for prostate cancer. Those men with compromised urinary function at baseline are at risk of late bladder toxicity; therefore, patient selection is paramount when considering hypofractionation. Hypofractionation offers economic and logistic advantages, reducing the burden of the very limited radiotherapy resources in most African countries. It also increases patient convenience. The most vital component is safe delivery, which necessitates accurate quality assurance measures and on-board imaging.

**Acknowledgements**

We thank Ruud Wortel, MD, for his help in collecting and reviewing the literature on hypofractionation.

**Competing interests**

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

**Authors’ contributions**

L.I. reviewed the literature and drafted the first version of the manuscript. B.H., P.K., and H.M.S contributed to the writing of the manuscript and approved the final version.